Stifel Financial Corp Cuts Position in Insmed Incorporated (NASDAQ:INSM)

Stifel Financial Corp trimmed its position in shares of Insmed Incorporated (NASDAQ:INSM) by 20.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,880 shares of the biopharmaceutical company’s stock after selling 6,974 shares during the period. Stifel Financial Corp’s holdings in Insmed were worth $1,856,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock valued at $1,257,838,000 after acquiring an additional 1,075,796 shares in the last quarter. Capital International Investors grew its holdings in shares of Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock valued at $491,357,000 after purchasing an additional 593,206 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Insmed by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock valued at $282,243,000 after purchasing an additional 273,759 shares in the last quarter. Artisan Partners Limited Partnership increased its stake in Insmed by 8.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company’s stock worth $215,842,000 after buying an additional 242,242 shares during the period. Finally, FIL Ltd lifted its holdings in Insmed by 8.1% during the 4th quarter. FIL Ltd now owns 2,638,160 shares of the biopharmaceutical company’s stock worth $182,139,000 after buying an additional 198,412 shares in the last quarter.

Insmed Trading Up 0.4 %

Shares of Insmed stock opened at $72.58 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company has a market capitalization of $13.20 billion, a P/E ratio of -12.98 and a beta of 0.84. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The company’s fifty day moving average is $73.31 and its two-hundred day moving average is $73.44.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Activity

In related news, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the transaction, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at $27,079,091.58. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Sara Bonstein sold 28,390 shares of Insmed stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $80.90, for a total value of $2,296,751.00. Following the completion of the sale, the chief financial officer now directly owns 155,506 shares in the company, valued at $12,580,435.40. This represents a 15.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 368,737 shares of company stock valued at $29,364,317. Company insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on INSM. Stifel Nicolaus cut their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Guggenheim reaffirmed a “buy” rating and issued a $101.00 price target on shares of Insmed in a research report on Tuesday, February 25th. JPMorgan Chase & Co. boosted their price objective on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Bank of America upped their target price on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research note on Thursday, March 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.